OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NATURLAND55

Naturland Holding Vagyonkezelo es Befektetesi Nyrt

PharmaceuticalsVerified

Naturland Holding Vagyonkezelo es Befektetesi Nyrt has an equal number of basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities at this time. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability and returns metrics are not available in the current dataset, making it difficult to compare its performance against the industry_config preferred metrics and cohort medians. This lack of data limits the ability to assess its financial health and competitive positioning. There is no detailed information on the company's segments or geographic exposure, which would be necessary to evaluate revenue concentration and diversification. Without this data, it is not possible to determine the extent of its exposure to specific markets or product lines. The growth trajectory of the company cannot be determined from the available data, as there are no numeric deltas or revenue history provided for the current or next fiscal year. This absence of growth indicators makes it challenging to forecast future performance. The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unknown. The lack of balance-sheet inputs and the absence of going-concern language in the source documents suggest that further investigation is needed to fully understand the company's financial stability. There are no recent events, such as filings or transcripts, provided in the dataset that would offer insight into the company's current operations or strategic direction. This lack of recent information limits the ability to assess any new developments or changes in the company's business strategy.

30-day price · NATURLAND+160.00 (+6.0%)
Low$2660.00High$2840.00Close$2820.00As of15 May, 00:00 UTC
Profile
CompanyNaturland Holding Vagyonkezelo es Befektetesi Nyrt
TickerNATURLAND.BU
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Naturland Holding Vagyonkezelo es Befektetesi Nyrt operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a confidence level of 0.92.

Naturland Holding Vagyonkezelo es Befektetesi Nyrt has an equal number of basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities at this time. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability and returns metrics are not available in the current dataset, making it difficult to compare its performance against the industry_config preferred metrics and cohort medians. This lack of data limits the ability to assess its financial health and competitive positioning. There is no detailed information on the company's segments or geographic exposure, which would be necessary to evaluate revenue concentration and diversification. Without this data, it is not possible to determine the extent of its exposure to specific markets or product lines. The growth trajectory of the company cannot be determined from the available data, as there are no numeric deltas or revenue history provided for the current or next fiscal year. This absence of growth indicators makes it challenging to forecast future performance. The risk assessment indicates a low level of dilution risk, but the liquidity risk remains unknown. The lack of balance-sheet inputs and the absence of going-concern language in the source documents suggest that further investigation is needed to fully understand the company's financial stability. There are no recent events, such as filings or transcripts, provided in the dataset that would offer insight into the company's current operations or strategic direction. This lack of recent information limits the ability to assess any new developments or changes in the company's business strategy.
Key takeaways
  • The company has no dilution from stock options or convertible securities as of the latest data.
  • The liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in the source documents.
  • Profitability and returns metrics are not available, limiting the ability to compare with industry benchmarks.
  • There is no detailed information on the company's segments or geographic exposure.
  • The growth trajectory and recent events are not available, making it difficult to forecast future performance or understand current operations.
  • # RATIONALES
  • margin_outlook_rationale: The margin outlook cannot be determined due to the lack of profitability data.
  • rd_outlook_rationale: The R&D outlook is not available as there is no information on research and development activities.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricNATURLANDActivity
Op margin18.2% medp25 18.2% · p75 24.6%
Net margin14.7% medp25 11.7% · p75 28.1%
Gross margin19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue4.9% medp25 4.2% · p75 6.3%
Debt / equity71.3% medp25 19.0% · p75 91.7%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 13:58 UTC#db85aadd
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 13:59 UTCJob: c7bd1a8a